Drugs /

auto3

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of autologous T-lymphocytes that have been transduced with a bicistronic retroviral vector encoding both an anti-CD19 chimeric antigen receptor (CAR) fused to OX40 co-stimulatory domain and an anti-CD22 CAR linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), optimized with a novel pentameric spacer derived from the collagen oligomeric matrix protein (COMP), with potential antineoplastic activity. Upon administration, the autologous anti-CD19/CD22 CAR T-cells AUTO3 bind to and induce selectivity in tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells. By simultaneously targeting two B-cell antigens, this preparation may minimize relapse due to single antigen loss in patients with B-cell malignancies.

Clinical Trials

View Clinical Trials for auto3

Auto3 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating auto3, 1 is phase 1/phase 2 (1 open).

BCL2 Fusion, BCL6 Fusion, and MYC Expression are the most frequent biomarker inclusion criteria for auto3 clinical trials.

Diffuse large B-cell lymphoma, diffuse large B-cell lymphoma, not otherwise specified, and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements are the most common diseases being investigated in auto3 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Auto3
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating auto3 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
auto-3, auto 3, anti-cd19/cd22 car autologous t-lymphocytes auto3, autologous anti-cd19/cd22 car-t cells auto3
Drug Target(s) [2]:
CD19, CD22
NCIT ID [1]:
C162620

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.